Sodium valproate (Evalex Iv)
Sodium valproate
Macleods Pharmaceuticals SA (Pty) Ltd
Registration
- Applicant
- Macleods Pharmaceuticals SA (Pty) Ltd
- Registrations
- 3
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Evalex 300 MG iv EACH 3,0 ml SOLUTION CONTAINS SODIUM VALPROATE 300,0 mg | 300 mg | 53066753/2.5/0667.664 | Registered | Not determined | None |
| Evalex 400 MG iv EACH 4,0 ml SOLUTION CONTAINS SODIUM VALPROATE 400,0 mg | 400 mg | 530668.66553/2.5/0668.665 | Registered | Not determined | None |
| Evalex 1 g iv EACH 10,0 ml SOLUTION CONTAINS SODIUM VALPROATE 1,0 g | 1 g | 53066953/2.5/0669.666 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
No structure available
This product's active ingredient could not be matched to a single known compound.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.